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Objective: To update the profile of patients attended with sepsis in specialised care centres 
in Spain, to analyse in-hospital mortality, disease management and costs between 2008 and 
2017.  
Methods: Admission records registered between 1 Jan 2008 and 31 Dec 2017 obtained 
from a Spanish National hospital discharge database for public and private hospitals. 
Centres are responsible for data codification, evaluation and confidentiality. The database is 
validated internally, and is subjected to periodic audits. Files corresponding to patients with 
sepsis and septic shock were selected by means of the International Statistical Classification 
of Diseases and Related Health Problems, 9th version and 10th version codes. These criteria 
claimed 311,674 records of 288,211 patients. Direct medical costs of secondary healthcare 
include expenses derived from the admission: examination, medication, treatment and costs 
of nutrition, personnel, medical equipment and resources. 
Results: More than 53% of all patients were males, with a mean age of 73.0 years. Fifty-
one per cent of the identified admissions were due to a sepsis without organ dysfunction, 
21.5% to sepsis with organ dysfunction, and 27.3% registered a septic shock. The incidence 
of sepsis increased 2.7 folds between 2008 and 2017, reaching a hospital incidence of 5.7 
per 10,000 inhabitants in 2017.Case fatality rate (CFR) was 23.2% and 35.0% in patients 
without and with organ dysfunction in 2017, respectively, and 42.9% in patient with septic 
shock, decreasing over time. Mean annual direct medical costs of specialised care over the 
study period were €6,664 and €8,084 per patient in patients with sepsis without and with 
organ dysfunction, respectively, and €11,359 per patient in those with septic shock.  
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Conclusions: The social and economic burden of sepsis in Spain continues to grow 
(incidence, total costs). Despite its general decreasing trend, CFR remains elevated, thus, 
patients could benefit from further research and protocol revision.  
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Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host 
response to infection in the Third International Consensus Definitions for Sepsis and Septic 
Shock (Sepsis-3) [1]. Sepsis can be caused by a wide range of organisms, and have varied 
origins, principally respiratory, abdominal or urinary [2]. It is a major cause of morbidity 
and mortality, remaining a challenge for clinicians and healthcare systems. Sepsis is 
assumed to represent a significant burden worldwide, with a global incidence of 43.7 per 
10,000 persons-year, with several studies indicating an increasing trend over the past 
decades [3,4].  
In Spain, the incidence of sepsis has been evaluated several times over the past decades, 
revealing a similar trend and an incidence of 8.7 per 10,000 persons between 2006 and 
2011, as evaluated in the Spanish national hospital discharge database including sepsis 
diagnosed in patients hospitalised for other reasons [5,6]. On the contrary, mortality 
appears to be decreasing, which serves as an indicator of the success of recent awareness 
campaigns and updated treatment guidelines [6]. Globally, the implementation of specific 
sepsis treatment guidelines and protocols has been critical for the decrease in sepsis-related 
mortality. The guidelines developed by the Surviving Sepsis Campaign (SSC) published in 
2004 and updated in 2016 have been associated with improved outcomes worldwide [7]; 
these focused on a series of bundles to be completed within 3 or 6 hours after the admission 
including blood culture, the administration of broad spectrum antibiotics and treatment to 
control hypotension and the repeated examination of vital signs and cardiovascular function 
[7,8,9]. Similarly, Sepsis-3 recommends the use of the Sequential Organ Failure 
Assessment (SOFA), which correlates with an increased probability of mortality, to 
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clinically characterise patients [1,10]. These criteria have provided a tool for early 
recognition that needs to be continuously updated [11,12]. 
The revision and improvement of protocols is one of the applications of epidemiology 
revisions, hence the growing interest on obtaining detailed and updated epidemiological 
data including sepsis and septic shock. Via this study, we aim to provide updated data 
regarding the characteristics of patients attended with sepsis in hospitals and specialised 
care centres in Spain, incidence, in-hospital mortality, disease management and costs, and 
to evaluate any temporal trends between 2008 and 2017. 
Methods  
Study design and setting 
Admission records of patients admitted in specialised care centres (hospitals and 
ambulatory) were analysed in a retrospective multicentre study, with a study period set 
from 1 Jan 2008 to 31 Dec 2017. Records were obtained from a Spanish National discharge 
database including public and private hospitals, which covers 90% of hospitals in Spain and 
is representative of all Spanish regions. The database includes anonymised admission data 
with diagnoses codified by means of the International Statistical Classification of Diseases 
and Related Health Problems, 9th version (ICD9) prior to 2016 and 10th version (ICD10) the 
years 2016 and 2017. Data codification is achieved at the hospital level by specialised 
doctors by using the Spanish ICD codification guides made available to health 
professionals. Hospitals are responsible for data codification, evaluation and 
confidentiality. The database is validated internally, and is subjected to periodic audits. In 
this process, errors and unreliable data are eliminated. Data inclusion was limited to 




Files corresponding to admissions with sepsis or septic shock as primary diagnosis (cause 
of admission) were selected via the ICD9 codes: 038.0, 038.1x, 038.2, 038.3, 038.4x, 
038.8, 038.9, 995.91, 995.92, 785.52, and ICD10 codes: A40.x, A41.x, R65.2x. A total of 
311,674 records complied with these criteria, corresponding to 288,211 patients that were 
classified according to sepsis severity: with or without organ dysfunction (without septic 
shock), and those that registered septic shock during the admission. Subsequently cases 
were classified according to the pathogen into streptococcal sepsis, staphylococcal sepsis, 
sepsis due to anaerobes, sepsis due to other Gram-negative organisms, other specified 
sepsis (i.e. sepsis due to Enterococcus) and sepsis due to unspecified organisms.  
Study variables  
The database codifies hospital discharge data on the patient profile and admission details: 
patients’ sex and age, Spanish region, date of admission, type of admission, date of 
discharge, type of discharge (including death), service that discharged the patient, length of 
stay, readmission rate, admission motive, secondary diagnoses registered during the 
admission, medical procedures performed and cost of the admission. 
Data analysis 
Single-patient data, obtained grouping recurrent admissions per each single patient, was 
used to characterise the population and calculate case fatality rate (CFR) defined as the 
proportion of in-hospital deaths registered in the study population. Sepsis age-adjusted 
incidence was extracted from the ministry of health database and was measured as the 
proportion of sepsis cases registered in specialised care centres within the population 
adjusted per age. All admission files were used to analyse the nature of admissions, length 
of stay, readmission (understood as a subsequent admission for the same cause within 30-
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days after discharge), medical procedures and costs. All the registered secondary diagnoses 
were identified by using ICD9 and ICD10 codes. 
Descriptive values are presented in mean (standard deviation [SD]), length of stay is 
presented in mean (standard error [SE]). Odds ratio (OR) with a 95% confidence interval 
(CI) were calculated for deceased patients, using non-deceased patients as the reference 
group. Two-tailed T-student or one-way analysis of variance were used as appropriate and 
two-sample Z tests were used to test for differences in sample proportions, with a p<0.05 
considered statistically significant. Statistical analyses were performed using IBM SPSS 
Statistics for Windows, Version 20.0. Released 2011 (IBM Corporation, Armonk, NY, 
USA) and Microsoft Excel© Professional Plus 2010 (Microsoft Corporation, Redmond, 
WA, USA). 
Direct medical costs of specialised healthcare were calculated based on admission costs 
indicated in the database; these are calculated according to the standardised average 
expenses of admissions and medical procedures determined by the Spanish Ministry of 
Health, which includes all expenses derived from the admission: examination, medication, 
treatment and costs of nutrition, personnel, medical equipment and resources.  
This study did not involve human participants and the database contains anonymised data 
with no identifying parameters, complying with the principles of Good Clinical Practice 
and the Declaration of Helsinki. In this context the Spanish legislation does not require 
patient consent and ethics committee approval [13].  
Results 
The 288,211 patients admitted with sepsis and septic shock over the ten year period were 
included in the analysis of patient characteristics (Table 1). Across all groups, more than 
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50% of the patients were males, with a mean age of 73.0 years. Over 51% of all registered 
admissions were due to a sepsis without organ dysfunction, 21.5% to sepsis with organ 
dysfunction without septic shock and 27.3% registered a septic shock. In most of the cases 
the pathogen was not specified; when specified, gram-negative organisms were 
predominant. The patients with a streptococcal sepsis (principally E. coli and Streptococcus 
pneumoniae) were the youngest.  
Sepsis incidence measured in specialised care facilities was 5.7 per 10,000 persons in 2017, 
increasing 2.7 folds over the study period (Figure 1A). Most of the cases were registered 
among patients aged 70 to 90 years (Figure 1B). 
CFR was 23.2% and 35.0% in patients without and with organ dysfunction in 2017, 
respectively, and 42.9% in patient with septic shock. CFR decreased significantly over the 
study period in patients with organ dysfunction and septic shock (2008 vs. 2017, p<0.001) 
(Figure 2A). CFR was higher in older patients throughout the study period (Figure 2B).  
Secondary conditions diagnosed upon admission are listed in Table 2. Acute conditions 
associated with organic dysfunction were predominant. Chronic conditions as essential 
hypertension, diabetes mellitus and malignant neoplasms, were found in between 20 and 
30% of admissions, with slight differences between patient groups. In addition, potential 
associations appeared in the group of deceased patients versus the remaining population. 
Acute respiratory failure was more common in deceased patients (OR=2.4; 95%CI 2.3-2.4); 
similar differences were observed for acute renal disease (OR=2.1; 95%CI 2.1-2.2), heart 
failure (OR=1.6; 95%CI 1.6-1.7), disorders of fluid electrolyte and acid-base balance 
(OR=2.2; 95%CI 2.1-2.2), malignant neoplasms (OR=1.7; 95%CI 1.7-1.8) and chronic 
ulcers of skin (OR=1.9; 95%CI 1.8-1.9).  
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In terms of healthcare use, over 96% of admissions in all groups were due to emergencies 
and attended by internal medicine departments in 63.5%, 67.1% and 47.1% of the cases in 
patients admitted due to sepsis without and with organ dysfunction and septic shock, 
respectively (Table 3). Mean length of stay was of 10.7 (SE=0.03) in patients without organ 
dysfunction and increased to 11.8 (SE=0.05) days in patients with organ dysfunction 
(p<0.001). In admissions that registered septic shock this was of 14.3 (SE=0.06) days 
(septic shock vs. no septic shock, p<0.001). Deceased patients registered a mean length of 
stay of 8.6 days (SE=0.04) (deceased patients vs. non deceased, p<0.001). The 30-day 
readmission rates oscillated between the 10 and 25%. 
The estimated mean annual direct costs of specialised care of sepsis were €6,664 and 
€8,084 per patient in patients with sepsis without and with organ dysfunction, respectively, 
and €11,359 per patient in those with septic shock (between groups, p<0.001) (Table 4), 
which, considering all patients (N=288,211), equalled a total of €247,412,912 per year. 
Overall, costs per patient decreased between 2011 and 2014 and increased again between 
2014 and 2017 (Figure 3). Mean admission cost was €7,940 over the study period and 
varied with the length of hospital stay. Mean admission cost per stays up to Q1 and longer 
than Q3 were €5,825-7,779; €6,703-10,132; and €8,035-17,735 in admissions due to sepsis 
without or with organ failure and septic shock, respectively (within groups, p<0.001). 
Discussion  
Several studies worldwide have described an increasing trend in the number of sepsis cases, 
which has correlated with an increasing interest in analysing its incidence, nature, 
management and costs.  
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The incidence of sepsis has been previously evaluated in Spain, covering a period of 14 
years (2000-2013) [5,6]. Data showed an increase that went from 3.3 per 10,000 persons-
year (2000-2004) to 4.5 (2010-2013), similarly to estimations in a global scale [2,6,14]. 
The same trend has been observed in smaller studies focused on patient subpopulations as 
those diagnosed with type 2 diabetes mellitus [15]. Herein the incidence per 10,000 was 2.1 
in 2008, increasing to 5.7 in 2015. A small decrease was observed the year 2016 after the 
introduction of ICD10, which limits comparability; yet, between 2016 and 2017 the 
increasing trend continued. Overall, this increase in incidence could be explained by the 
improved coding of sepsis that has been demonstrated in certain European countries, as 
Germany, as well as the increased sepsis awareness [16]. 
On the contrary, data confirms a decrease in mortality, measured as the reduction of CFR. 
This parameter was 45.4% in Spain in 2006, and decreased to 40.2% in 2011 [5]; our data 
estimated a CFR of 23.2% and 35.0% in patients without and with organ dysfunction in 
2017, respectively, and 42.9% in patients with septic shock, overall, decreasing over the 
study period presumably due to the improved treatment algorithms and guidelines 
promoted at the European and global level [1,7,8]. In Spain, European protocols are used, 
with compliance rates that have increased considerably since 2008 directly affecting health 
outcomes, reducing mortality rates in patients with severe sepsis and septic shock [17-20]. 
In addition, an effect of the increased register of sepsis cannot be discarded.   
Regarding patients’ profile, mean age registered upon admission was 73.0 (18.6) years. 
Data from the period 2000-2013 showed a significant temporal increase of patients’ age, 
that in that case averaged 69.7 (20.0) years [6].  
A predominance of cases caused by Gram-negative bacteria, principally E. coli, would 
coincide with previous estimations, while the origin of the infection could not be directly 
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evaluated [5,21]. Most admissions registered symptoms of organ dysfunction, although 
chronic conditions including hypertension and diabetes were also present. Renal, cardiac 
and respiratory symptoms were associated with in-hospital mortality, as well as the 
disorders of fluid electrolyte and acid-base balance and malignant neoplasms. On the other 
hand, even though liver dysfunction is considered a common symptom of sepsis, liver 
affectation was not depicted clearly in this population [22]; the lack of laboratory test 
results impeded a formal analysis of laboratory abnormalities. 
Most of the admissions were not scheduled, with hospital stays over the 10 days. Relatively 
high 30-day readmission rates have been previously described in patients with sepsis, 
attributed primarily to infections and pulmonary complications [23]. 
These factors had an influence on the medical costs of the disease in specialised care, 
known to correlate with age, severity, admission and attention characteristics [24,25]. 
Overall, the mean annual cost per patient in the study period was €6,664 and €8,084 in 
patients with sepsis without and with organ dysfunction, respectively, and €11,359 per 
patient in those with septic shock; whereas in the period 2000-2013 average costs reached 
the €9,090 following an increasing trend [6]. Herein, cost per patient appeared to decrease  
between the years 2011 and 2014, likely to be an effect of the economic crisis that had great 
effects on the Spanish medical and pharmaceutical expenditure in that period [26,27]. Data 
suggest a recovery of the increasing trend after 2014. As expected, admission costs 
increased with longer hospital stays.  
A series of factors limited the results of this study. The update of the database codification 
to ICD10 in 2016 generated inconsistencies in the data, likely to derive from centres not 
adhering to the new system. Incidence was calculated using only patients admitted with 
sepsis in specialised care centres; this could origin an underestimation of this rate. Data 
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selection method should be taken into account for data interpretation. Finally, the lack of 
laboratory test results in admission files hampered the evaluation of organ dysfunction and 
overall severity of the symptoms.  
Conclusions 
Sepsis is a major cause of mortality in Spain and represents a significant economic burden 
that continues to grow. Patients with sepsis with organ dysfunction and septic shock present 
elevated case fatality rates (35.0% and 42.9% in 2017), despite its globally decreasing trend 
presumably due to the successful application and revision of clinical protocols. Research to 
corroborate and update these results will be necessary in the upcoming years. 
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Table 1 Characteristics of patients admitted with sepsis (2008-2017).  
Patient cluster Admissions, N Patients, N Males, % Age (SD) 
All files 311,674 288,211 53.7 73.0 (18.6) 
Sepsis without organ dysfunction 159,343 145,155 53.1 72.6 (20.5) 
Streptococcal sepsis 7,519 7,127 59.0 62.6 (27.3) 
Staphylococcal sepsis 6,534 6,120 59.8 68.6 (21.3) 
Sepsis due to anaerobes 944 879 55.2 73.4 (17.5) 
Sepsis due to other Gram-negative 
organisms 
42,935 39,175 50.2 73.4 (17.7) 
Other specified sepsis 5,455 4,870 57.8 71.8 (20.9) 
Sepsis of unspecified organism 95,956 86,984 53.1 73.5 (20.8) 
Sepsis with organ dysfunction 67,146 62,851 53.0 75.9 (15.9) 
Streptococcal sepsis 3,507 3,369 59.5 68.3 (19.9) 
Staphylococcal sepsis 2,666 2,544 60.6 72.3 (17.0) 
Sepsis due to anaerobes 378 353 54.1 74.4 (16.4) 
Sepsis due to other Gram-negative 
organisms 
13,865 12,957 50.1 74.9 (15.4) 
Other specified sepsis 3,642 3,436 53.9 74.8 (17.0) 
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Sepsis of unspecified organism 43,088 40,192 52.8 77.2 (15.3) 
Septic shock 85,185 80,205 55.5 71.4 (16.6) 
Streptococcal sepsis 5,209 5,064 62.6 62.9 (19.5) 
Staphylococcal sepsis 3,541 3,436 61.6 67.1 (17.3) 
Sepsis due to anaerobes 567 546 52.2 68.7 (16.6) 
Sepsis due to other Gram-negative 
organisms 
18,641 17,808 52.8 70.8 (15.6) 
Other specified sepsis 4,471 4,293 56.9 70.5 (16.9) 



















Acute conditions - - - - 
Acute heart disease 43.9 62.0 55.7 62.9 
    Heart failure 10.7 19.8 15.6 18.4 
    Atrial fibrillation 16.7 20.6 18.2 22.1 
Infection of the urinary system 38.1 31.6 25.0 25.7 
Acute renal disease 20.9 72.8 63.1 62.9 
    Acute kidney failure 19.6 52.7 47.6 43.5 
Disorders of fluid electrolyte and 
acid-base balance 
19.1 31.8 28.1 32.6 
Acute respiratory failure 9.8 29.4 26.9 30.1 
Bacterial pneumonia 11.3 17.9 16.4 17.3 
Chronic conditions - - - - 
Hypertension 34.0 32.6 28.9 31.8 
Diabetes mellitus 29.8 30.7 24.2 28.4 
Malignant neoplasms 23.3 23.5 25.6 32.1 
Chronic ulcer of skin 22.4 24.0 15.7 29.1 
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Anaemia 17.8 18.8 14.1 13.9 
Hyperlipidaemia and 
hypercholesterolemia 
16.8 15.7 13.1 13.3 
Chronic kidney disease 15.3 18.8 13.9 17.7 
Chronic obstructive pulmonary 
disease 
14.2 15.6 13.7 14.1 

















Sepsis without organ dysfunction 96.4 10.7 (0.03) 18.2 21.4 
Streptococcal sepsis 91.3 12.9 (0.15) 15.8 11.3 
Staphylococcal sepsis 89.8 17.0 (0.28) 24.6 20.2 
Sepsis due to anaerobes 89.8 14.9 (0.62) 22.7 15.0 
Sepsis due to other Gram-negative 
organisms 
87.9 11.0 (0.05) 18.5 9.4 
Other specified sepsis 86.1 11.9 (0.17) 21.1 17.3 
Sepsis of unspecified organism 87.6 9.9 (0.03) 17.6 27.9 
Sepsis with organ dysfunction 97.1 11.8 (0.05) 18.4 42.8 
Streptococcal sepsis 92.2 15.2 (0.30) 12.2 27.1 
Staphylococcal sepsis 92.8 18.5 (0.37) 22.6 41.4 
Sepsis due to anaerobes 90.7 15.6 (0.73) 23.5 33.3 
Sepsis due to other Gram-negative 
organisms 
90.6 13.1 (0.12) 18.5 24.1 
Other specified sepsis 91.3 13.1 (0.30) 21.3 42.0 
Sepsis of unspecified organism 90.8 10.5 (0.06) 18.3 50.2 
Septic shock 96.5 14.3 (0.06) 18.0 47.3 
Streptococcal sepsis 96.4 20.0 (0.33) 11.7 31.3 
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Staphylococcal sepsis 94.5 22.0 (0.41) 21.1 47.8 
Sepsis due to anaerobes 96.3 20.4 (1.05) 22.9 33.6 
Sepsis due to other Gram-negative 
organisms 
96.6 16.5 (0.14) 18.5 27.5 
Other specified sepsis 95.4 15.5 (0.30) 18.3 43.7 








Table 4 Direct medical costs of specialised care associated with sepsis (2008-2017).  
 
Patient cluster Annual cost Cost per patient 
Sepsis without organ dysfunction € 103,015,558 € 6,664 
Streptococcal sepsis € 5,193,776 € 7,036 
Staphylococcal sepsis € 4,819,885 € 7,489 
Sepsis due to anaerobes € 642,211 € 6,955 
Sepsis due to other Gram-negative 
organisms 
€ 26,538,863 € 6,347 
Other specified sepsis € 3,633,741 € 6,728 
Sepsis of unspecified organism € 62,187,082 € 6,701 
Sepsis with organ dysfunction € 52,006,723 € 8,084 
Streptococcal sepsis € 3,234,226 € 9,565 
Staphylococcal sepsis € 2,485,410 € 9,502 
Sepsis due to anaerobes € 320,357 € 8,438 
Sepsis due to other Gram-negative 
organisms 
€ 10,546,086 € 8,067 
Other specified sepsis € 2,915,835 € 8,156 
Sepsis of unspecified organism € 32,504,810 € 7,870 
Septic shock € 92,390,630 € 11,359 
Streptococcal sepsis € 7,086,419 € 13,801 
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Staphylococcal sepsis € 4,991,391 € 14,279 
Sepsis due to anaerobes € 728,305 € 13,008 
Sepsis due to other Gram-negative 
organisms 
€ 20,378,961 € 11,321 
Other specified sepsis € 5,127,978 € 11,505 
















Figure 2 (A) Annual case fatality rate (CFR) by sepsis severity and (B) age specific 
CFR by sepsis severity (2008-2017). 
 
Figure 3 Annual medical cost per patient by sepsis severity (2008-2017)  
 
